Anti-IgE therapy results in decreased myeloid dendritic cells in asthmatic airways

J Allergy Clin Immunol. 2010 May;125(5):1157-1158.e5. doi: 10.1016/j.jaci.2010.01.020. Epub 2010 Mar 20.

Abstract

Anti-IgE treatment of intermittent to mild-persistent asthma in a cohort of seven volunteers resulted in improved allergen-induced airway hyperreactivity and a significant reduction in the number of airway myeloid dendritic cells.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Asthma / drug therapy*
  • Asthma / immunology
  • Bronchi* / cytology
  • Bronchi* / immunology
  • Bronchoalveolar Lavage Fluid / cytology
  • Bronchoalveolar Lavage Fluid / immunology
  • Dendritic Cells* / cytology
  • Dendritic Cells* / immunology
  • Female
  • Humans
  • Male
  • Myeloid Cells* / cytology
  • Myeloid Cells* / immunology
  • Omalizumab
  • Treatment Outcome

Substances

  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • anti-IgE antibodies
  • Omalizumab